Huaren Pharmaceutical Co., Ltd. (300110.SZ)
CNY 2.9
(0.0%)
CNY 2.9
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.88 Billion CNY | -2.15% |
| 2022 | 1.92 Billion CNY | -5.27% |
| 2021 | 2.02 Billion CNY | 278.25% |
| 2020 | 536.65 Million CNY | 166.06% |
| 2019 | 201.7 Million CNY | -71.87% |
| 2018 | 717 Million CNY | -25.83% |
| 2017 | 966.64 Million CNY | 12.66% |
| 2016 | 858.05 Million CNY | -16.96% |
| 2015 | 1.03 Billion CNY | 21.92% |
| 2014 | 847.55 Million CNY | 27.45% |
| 2013 | 665 Million CNY | 195.56% |
| 2012 | 225 Million CNY | 0.0% |
| 2011 | - CNY | 0.0% |
| 2010 | - CNY | -100.0% |
| 2009 | 270 Million CNY | 8.43% |
| 2008 | 249 Million CNY | 84.86% |
| 2007 | 134.7 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 1.59 Billion CNY | -40.38% |
| 2024 Q1 | 1.68 Billion CNY | -10.38% |
| 2024 Q2 | 1.65 Billion CNY | -1.83% |
| 2023 Q1 | 1.88 Billion CNY | -2.0% |
| 2023 FY | 1.88 Billion CNY | -2.15% |
| 2023 Q2 | 2.1 Billion CNY | 11.79% |
| 2023 Q3 | 1.94 Billion CNY | -7.9% |
| 2023 Q4 | 1.88 Billion CNY | -3.03% |
| 2022 Q2 | 2.13 Billion CNY | 4.91% |
| 2022 Q4 | 1.92 Billion CNY | 0.25% |
| 2022 FY | 1.92 Billion CNY | -5.27% |
| 2022 Q3 | 1.91 Billion CNY | -10.36% |
| 2022 Q1 | 2.03 Billion CNY | 0.48% |
| 2021 Q3 | 1.93 Billion CNY | 36.07% |
| 2021 Q1 | 822.22 Million CNY | 53.21% |
| 2021 Q2 | 1.42 Billion CNY | 72.91% |
| 2021 Q4 | 2.02 Billion CNY | 4.93% |
| 2021 FY | 2.02 Billion CNY | 278.25% |
| 2020 FY | 536.65 Million CNY | 166.06% |
| 2020 Q3 | 245 Million CNY | 81.62% |
| 2020 Q2 | 134.9 Million CNY | -39.37% |
| 2020 Q4 | 536.65 Million CNY | 119.04% |
| 2020 Q1 | 222.5 Million CNY | 10.31% |
| 2019 FY | 201.7 Million CNY | -71.87% |
| 2019 Q3 | 250.6 Million CNY | -42.75% |
| 2019 Q4 | 201.7 Million CNY | -19.51% |
| 2019 Q1 | 617.9 Million CNY | -13.82% |
| 2019 Q2 | 437.7 Million CNY | -29.16% |
| 2018 Q4 | 717 Million CNY | -3.36% |
| 2018 FY | 717 Million CNY | -25.83% |
| 2018 Q1 | 699.8 Million CNY | -27.61% |
| 2018 Q2 | 740.5 Million CNY | 5.82% |
| 2018 Q3 | 741.9 Million CNY | 0.19% |
| 2017 Q4 | 966.64 Million CNY | 4.56% |
| 2017 FY | 966.64 Million CNY | 12.66% |
| 2017 Q3 | 924.47 Million CNY | 1.95% |
| 2017 Q2 | 906.79 Million CNY | 13.56% |
| 2017 Q1 | 798.5 Million CNY | -6.94% |
| 2016 FY | 858.05 Million CNY | -16.96% |
| 2016 Q4 | 858.05 Million CNY | -7.08% |
| 2016 Q3 | 923.4 Million CNY | -6.21% |
| 2016 Q2 | 984.58 Million CNY | -3.2% |
| 2016 Q1 | 1.01 Billion CNY | -1.57% |
| 2015 FY | 1.03 Billion CNY | 21.92% |
| 2015 Q1 | 983.43 Million CNY | 16.03% |
| 2015 Q2 | 961.9 Million CNY | -2.19% |
| 2015 Q3 | 991.82 Million CNY | 3.11% |
| 2015 Q4 | 1.03 Billion CNY | 4.19% |
| 2014 Q1 | 590 Million CNY | -11.28% |
| 2014 FY | 847.55 Million CNY | 27.45% |
| 2014 Q3 | 745.22 Million CNY | 11.23% |
| 2014 Q2 | 670 Million CNY | 13.56% |
| 2014 Q4 | 847.55 Million CNY | 13.73% |
| 2013 Q3 | 355 Million CNY | 12.7% |
| 2013 Q4 | 665 Million CNY | 87.32% |
| 2013 FY | 665 Million CNY | 195.56% |
| 2013 Q1 | 345 Million CNY | 53.33% |
| 2013 Q2 | 315 Million CNY | -8.7% |
| 2012 Q1 | 180 Million CNY | 0.0% |
| 2012 Q4 | 225 Million CNY | -13.46% |
| 2012 FY | 225 Million CNY | 0.0% |
| 2012 Q3 | 260 Million CNY | 0.0% |
| 2012 Q2 | - CNY | -100.0% |
| 2011 Q1 | - CNY | 0.0% |
| 2011 FY | - CNY | 0.0% |
| 2011 Q3 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 Q4 | - CNY | 0.0% |
| 2010 Q2 | 280.91 Million CNY | 0.0% |
| 2010 Q4 | - CNY | -100.0% |
| 2010 Q3 | 40 Million CNY | -85.76% |
| 2010 FY | - CNY | -100.0% |
| 2009 Q4 | 270 Million CNY | 0.0% |
| 2009 FY | 270 Million CNY | 8.43% |
| 2008 FY | 249 Million CNY | 84.86% |
| 2007 FY | 134.7 Million CNY | 0.0% |